Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right deals done for biopharma and medtech companies.
Walk with us. Together, we’ll build lasting value.
Japan collaboration for a phase 2 orphan dermatology asset AC-203, a novel topical treatment for epidermolysis bullosa simplex, December 2020
Advised on Chinese joint venture and license with 3E Bioventures, November 2020
Nevakar and Zhaoke Ophthalmology enter into licensing agreement for NVK-002, October 2020
IPO Advisory assignment helping raise $210M in a NASDAQ IPO, October 2020
Corporate, R&D, BD, and financing strategy and commercial analytics with strategic transactions and capital markets execution
Global reach with on-the-ground local presence and company and investor relationships in all major life science markets
Integration of upfront preparation with downstream execution with a transaction lens
Each quarter we compile key statistics and trends on strategic transactions and financings.
You can download your report here.
Locust Walk has closed high value transactions for multiple clients across a variety of therapeutic areas and modalities. The breadth of our success includes sell-side, buy-side and financing deals. Examples of recent client engagements where Locust Walk served as a transaction advisor are listed below. We would encourage you to click on each case study and/or press release to learn about each assignment in greater detail.